PharmEnable Entered into a Multi-Target Collaboration with Denali to Discover Therapies for the Treatment of Neurodegenerative Disease
- PharmEnable to receive an up front and will be eligible to receive development and commercial milestones. Denali will be responsible for the further lead optimization, development, and commercialization of the products
- The collaboration will combine PharmEnable’ AI drug discovery platform with Denali's expertise in delivery across the BBB and neurodegeneration to identify therapeutically relevant small molecule chemical matter against challenging targets
- PharmEnable's drug discovery platform is a potent engine for creating novel chemical entities against a difficult target. Additionally, joint research programs are to be initiated over the next 2yrs. against multiple undisclosed targets
Ref: Denali | Image: Denali
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.